The new laboratory in Atlanta, Georgia, will offer clinical test services for hereditary diseases, oncology, and post-transplant monitoring.
The laboratory has already processed its first commercial test, examining a patient sample for fetal Rhesus D blood group status, states the company in a press release.
“The opening of our new CLIA-certified laboratory in Atlanta is a major milestone in increasing Devyser’s presence in the US, the biggest diagnostic market in the world. I am very proud of the Devyser team that has enabled us to have a fully operational and CLIA-certified laboratory within such a short time. We are excited to expand our clinical testing offering in the laboratory,” says Fredrik Alpsten, CEO at Devyser.
The laboratory will scale as demand grows and will initially focus on providing clinical testing services for healthcare providers and patients in the US. Devyser is currently working on reimbursement for each of the tests that will be part of the CLIA-certified laboratory test offering, it states.
Photo of the opening ceremony of the new CLIA-certified laboratory: Devyser
